AccuStem Sciences, Inc.(the “Company”) is a life sciences company focused on improving outcomes for patients with cancer. Our plan is to develop and commercialize a variety of products in the diagnostics, pharmaceutical and medical device spaces that enable more informed treatment planning and more effective treatment options for patients. Our initial approach will be the commercialization of a proprietary genomic platform, StemPrint, for recurrence risk stratification of different types of cancer. StemPrint was developed to measure the “stemness” of tumors, or how likely a cancer is to recur or be resistant to standard treatments, which could impact how patients are managed in oncology clinics. To augment this unique offering we also plan to provide ancillary commodity testing (e.g., hereditary genetic testing, somatic mutation testing) to provide additional information and value to our clients.
Company profile
Ticker
ACUT, ACUT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AccuStem Sciences Ltd
SEC CIK
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
10 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
10-Q
2023 Q1
Quarterly report
5 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
15 Feb 23
S-1/A
IPO registration (amended)
19 Jan 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Dec 22 | Cerrone Gabriel M | Common Stock | Buy | Acquire P | Yes | No | 1.4 | 5,000 | 7.00 k | 3,864,452 |
2 Dec 22 | Cerrone Gabriel M | Common Stock | Buy | Acquire P | Yes | No | 1.42 | 3,729 | 5.30 k | 3,859,452 |
18 Nov 22 | Cerrone Gabriel M | Common Stock | Buy | Acquire P | Yes | No | 1.05 | 24,500 | 25.73 k | 3,855,723 |